1. Home
  2. TRUG vs NEUP Comparison

TRUG vs NEUP Comparison

Compare TRUG & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRUG
  • NEUP
  • Stock Information
  • Founded
  • TRUG 1983
  • NEUP 1996
  • Country
  • TRUG United States
  • NEUP United States
  • Employees
  • TRUG N/A
  • NEUP N/A
  • Industry
  • TRUG
  • NEUP
  • Sector
  • TRUG
  • NEUP
  • Exchange
  • TRUG NYSE
  • NEUP Nasdaq
  • Market Cap
  • TRUG 10.9M
  • NEUP 9.3M
  • IPO Year
  • TRUG N/A
  • NEUP N/A
  • Fundamental
  • Price
  • TRUG $0.23
  • NEUP $4.74
  • Analyst Decision
  • TRUG Strong Buy
  • NEUP Strong Buy
  • Analyst Count
  • TRUG 1
  • NEUP 1
  • Target Price
  • TRUG $2.00
  • NEUP $21.00
  • AVG Volume (30 Days)
  • TRUG 1.8M
  • NEUP 10.9K
  • Earning Date
  • TRUG 04-15-2025
  • NEUP 05-23-2025
  • Dividend Yield
  • TRUG N/A
  • NEUP N/A
  • EPS Growth
  • TRUG N/A
  • NEUP N/A
  • EPS
  • TRUG N/A
  • NEUP N/A
  • Revenue
  • TRUG $21,858,864.00
  • NEUP $662,715.00
  • Revenue This Year
  • TRUG $24.05
  • NEUP N/A
  • Revenue Next Year
  • TRUG $31.65
  • NEUP N/A
  • P/E Ratio
  • TRUG N/A
  • NEUP N/A
  • Revenue Growth
  • TRUG 6.19
  • NEUP N/A
  • 52 Week Low
  • TRUG $0.22
  • NEUP $2.12
  • 52 Week High
  • TRUG $1.60
  • NEUP $15.24
  • Technical
  • Relative Strength Index (RSI)
  • TRUG 36.70
  • NEUP N/A
  • Support Level
  • TRUG $0.21
  • NEUP N/A
  • Resistance Level
  • TRUG $0.25
  • NEUP N/A
  • Average True Range (ATR)
  • TRUG 0.03
  • NEUP 0.00
  • MACD
  • TRUG -0.00
  • NEUP 0.00
  • Stochastic Oscillator
  • TRUG 16.12
  • NEUP 0.00

About TRUG TRUGOLF HOLDINGS INC

TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games (including Links, a sports game for PC), hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.

About NEUP Neuphoria Therapeutics Inc. Common Stock

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

Share on Social Networks: